2,150,000 Shares in BioCryst Pharmaceuticals, Inc. $BCRX Bought by Elmind Capital LP

Elmind Capital LP acquired a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the fourth quarter, HoldingsChannel reports. The fund acquired 2,150,000 shares of the biotechnology company’s stock, valued at approximately $16,770,000. BioCryst Pharmaceuticals accounts for 4.9% of Elmind Capital LP’s holdings, making the stock its 7th biggest holding.

A number of other institutional investors have also recently bought and sold shares of BCRX. Royal Bank of Canada raised its holdings in BioCryst Pharmaceuticals by 2.4% in the first quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock worth $476,000 after purchasing an additional 1,458 shares during the period. Cetera Investment Advisers raised its holdings in BioCryst Pharmaceuticals by 13.8% in the fourth quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 1,494 shares during the period. Captrust Financial Advisors raised its holdings in BioCryst Pharmaceuticals by 7.4% in the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock worth $198,000 after purchasing an additional 1,527 shares during the period. Counterweight Ventures LLC raised its holdings in BioCryst Pharmaceuticals by 2.1% in the fourth quarter. Counterweight Ventures LLC now owns 95,384 shares of the biotechnology company’s stock worth $744,000 after purchasing an additional 2,000 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in BioCryst Pharmaceuticals by 26.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Wedbush cut their target price on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Evercore assumed coverage on shares of BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 target price on the stock. Wall Street Zen lowered shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Needham & Company LLC cut their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.70.

BioCryst Pharmaceuticals Stock Up 0.3%

BioCryst Pharmaceuticals stock opened at $8.95 on Thursday. The stock has a market capitalization of $2.27 billion, a PE ratio of -5.03 and a beta of 0.57. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.00 and a twelve month high of $10.32. The company has a 50 day moving average of $8.92 and a 200-day moving average of $8.16.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04). The company had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.20 EPS. Equities analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.66 EPS for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.